003017 大洋生物
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)5.9829.1456.1885.0188.172
总资产报酬率 ROA (%)3.5895.7523.9843.2745.601
投入资产回报率 ROIC (%)4.0576.4444.4383.7006.241

边际利润分析
销售毛利率 (%)21.42322.89819.55018.08413.822
营业利润率 (%)9.34610.5388.2836.1225.594
息税前利润/营业总收入 (%)9.2999.8247.5304.8795.619
净利润/营业总收入 (%)8.4949.5727.0045.4397.629

收益指标分析
经营活动净收益/利润总额(%)83.74496.92191.10095.71761.628
价值变动净收益/利润总额(%)-1.965-0.2660.5093.4955.075
营业外收支净额/利润总额(%)-0.303-3.108-5.199-19.804-3.028

偿债能力分析
流动比率 (X)0.9851.2191.2161.5381.523
速动比率 (X)0.7661.0491.0051.1841.257
资产负债率 (%)41.83537.48936.31034.81434.681
带息债务/全部投入资本 (%)32.66827.48527.59023.80522.474
股东权益/带息债务 (%)199.697257.216254.538308.124329.963
股东权益/负债合计 (%)138.533165.999175.243187.237188.341
利息保障倍数 (X)-501.194-24.773-21.920-21.11929.751

营运能力分析
应收账款周转天数 (天)30.80825.07619.22521.03117.565
存货周转天数 (天)57.98350.79066.88466.70256.946